Biological Activity
Group I p21-activated kinase (PAK) inhibitor (IC50 = 2.5 μM at PAK1). Targets the autoregulatory mechanism and promotes the inactive conformation of PAKs. Inhibits PAK1-mediated signaling in vivo; potential anti-tumor agent. Negative control PIR 3.5 (Cat. No. 4212) available.
Compound Libraries
IPA 3 is also offered as part of the Tocriscreen Stem Cell Toolbox. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 350.45 |
| Formula | C20H14O2S2 |
| Storage | Store at +4°C |
| Purity | ≥96% (HPLC) |
| CAS Number | 42521-82-4 |
| PubChem ID | 521106 |
| InChI Key | RFAXLXKIAKIUDT-UHFFFAOYSA-N |
| Smiles | OC2=C(SSC3=C(O)C=CC4=C3C=CC=C4)C1=CC=CC=C1C=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 26.28 | 75 | |
| ethanol | 3.5 | 10mM with gentle warming |
Preparing Stock Solutions
The following data is based on the product molecular weight 350.45. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.85 mL | 14.27 mL | 28.53 mL |
| 5 mM | 0.57 mL | 2.85 mL | 5.71 mL |
| 10 mM | 0.29 mL | 1.43 mL | 2.85 mL |
| 50 mM | 0.06 mL | 0.29 mL | 0.57 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Kumar et al (2006) p21-activated kinases in cancer. Nat.Rev.Cancer 6 459 PMID: 16723992
Deacon et al (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem.Biol. 15 322 PMID: 18420139
Takahashi and Suzuki (2009) Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/op18 to Pak1-WAVE2-kinesin complex. Cell.Signal. 21 695 PMID: 19162178
Viaud and Peterson (2009) An allosteric kinase inhibitor binds the p21-activated kinase (Pak) autoregulatory domain covalently. Mol.Cancer Ther. 8 2559 PMID: 19723886
Wang et al (2016) P21-activated kinase inhibitors FRAX486 and IPA3: inhibition of prostate stromal cell growth and effects on smooth muscle contraction in the human prostate. PLoS One 11 e0153312 PMID: 27071060
Keywords: IPA 3, supplier, Group, I, p21-activated, kinases, PAK, PAK1, inhibitors, inhibits, IPA3, P21-activated, Kinases, P21-activated, Kinases, Tocris Bioscience
